Lumos Diagnostics Holdings Limited develops, manufactures, and commercializes point-of-care diagnostic products for diagnosis and management of infectious diseases in the United States. The company’s products include FebriDx, a point-of-care diagnostic test for detecting and differentiating viral and bacterial respiratory infections; and ViraDx, a three-in-one point-of-care test for influenza A, influenza B, and COVID-19. It also provides assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos Diagnostics Holdings Limited was incorporated in 2018 and is based in Carlsbad, California.
Metrics to compare | LDX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipLDXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −14.9x | −6.0x | −0.6x | |
PEG Ratio | −0.35 | −0.29 | 0.00 | |
Price/Book | 17.4x | 1.2x | 2.6x | |
Price / LTM Sales | 8.7x | 5.5x | 3.3x | |
Upside (Analyst Target) | −52.4% | 6.6% | 42.1% | |
Fair Value Upside | Unlock | 21.4% | 6.6% | Unlock |